Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 at BMO Capital Markets

Replimune Group (NASDAQ:REPL) had its price target upped by BMO Capital Markets from $14.00 to $18.00 in a report published on Friday,Benzinga reports. The firm currently has an outperform rating on the stock.

REPL has been the topic of several other reports. JPMorgan Chase & Co. upped their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm began coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Friday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $17.00.

Replimune Group Stock Performance

Replimune Group stock opened at $14.93 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock’s 50 day moving average is $11.51 and its 200 day moving average is $9.67. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts predict that Replimune Group will post -3.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 8.80% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its stake in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Replimune Group during the second quarter valued at approximately $57,000. Arizona State Retirement System bought a new stake in shares of Replimune Group during the second quarter valued at approximately $108,000. Quest Partners LLC raised its stake in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of Replimune Group during the third quarter valued at approximately $133,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.